VSTM logo

Verastem, Inc.

VSTM
Healthcare|Biotechnology|US
$8.41
-0.97 (-10.34%)
Cash / Share
$1.71
Next Earnings Report
Mar 3, 2027
EPS est. -$0.37 · Revenue est. $31.2M
Financing Filings (last 12 months)
5
Shelf registrations / offering prospectuses — latest Nov 5, 2026 (S-3ASR). Possible dilution.

Upcoming Data Readouts (16)

Dec 2026
Est. completion
Early P1Glioblastoma
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
NCT05798507n=14
Mar 2027
Est. completion
P2Mesonephric Gynecologic Cancer
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
NCT05787561n=40
Apr 2027
Est. completion
P2Low-Grade Serous Ovarian Cancer
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
NCT06394804n=20
Jun 2027
Est. completion
P2Colorectal Cancer
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
NCT07659795n=150
Jun 2027
Est. completion
P2Non-Small Cell Lung Cancer
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782n=105
Jun 2027
Est. completion
P2Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
NCT07644559n=185
Aug 2027
Est. completion
P2Thyroid Cancer
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
NCT06007924n=30
Dec 2027
Est. completion
P2Endometrioid Cancer
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
NCT05512208n=55
Dec 2027
Est. completion
P1P2Breast Cancer
VS-6766+Abema+Fulv in Met HR+/HER- BC
NCT05608252n=63
Jan 2028
Est. completion
P1P2Cutaneous Melanoma
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
NCT06194929n=33
Aug 2028
Est. completion
P1Phase IB
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
NCT07318324n=31
Oct 2028
Est. completion
P3Low Grade Serous Ovarian Cancer
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
NCT06072781n=270
Nov 2028
Est. completion
P2Gastric Cancer
Avutometinib and Defactinib in Diffuse Gastric Cancer
NCT06487221n=27
Dec 2028
Est. completion
P1P2Pancreatic Ductal Adenocarcinoma
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
NCT07020221n=616
Sep 2029
Est. completion
P1P2Glioblastoma Multiforme (GBM)
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
NCT06630260n=182
Apr 2030
Est. completion
P2Pancreatic Adenocarcinoma
Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
NCT07126158n=36

Awaiting Results (6)

Trials past primary completion date but still active — data readout may be imminent.

Aug 2026
P1P2
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
NCT05669482
Jun 2026
P1P2
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
NCT05074810
Feb 2026
P2
Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
NCT04331041
Dec 2025
P2
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
NCT06682572
Nov 2024
P2
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
NCT04625270
Apr 2023
P1
Phase I Trial of Defactinib and VS-6766.
NCT03875820

Recent Press Releases

Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
Nov 5, 2026 · Business Wire
Verastem Oncology to Participate in Upcoming November Investor Conferences
Nov 2, 2026 · Business Wire
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
Oct 22, 2026 · Business Wire
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Oct 14, 2026 · Business Wire
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
Oct 14, 2026 · Business Wire
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
Oct 14, 2026 · Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 5, 2026 · Business Wire
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
Oct 2, 2026 · Business Wire
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
Sep 28, 2026 · Business Wire
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
Sep 24, 2026 · Business Wire

SEC Filings (118)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Nov 5, 2026S-3ASRShelf registrationDocumentIndex
Nov 5, 2026S-8Employee stock planDocumentIndex
Nov 5, 20268-KMaterial eventDocumentIndex
Nov 5, 202610-QQuarterly reportDocumentIndex
Oct 30, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Oct 14, 20268-KMaterial eventDocumentIndex
Oct 14, 2026424B5Offering prospectusDocumentIndex
Oct 14, 2026424B5Offering prospectusDocumentIndex
Oct 14, 20268-KMaterial eventDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 7, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 7, 20268-KMaterial eventDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Aug 6, 202610-QQuarterly reportDocumentIndex
Jul 31, 2026SC 13GPassive 5%+ stakeDocumentIndex
Jul 30, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jul 8, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jun 23, 20268-KMaterial eventDocumentIndex
Jun 17, 20268-KMaterial eventDocumentIndex
May 29, 2026S-8Employee stock planDocumentIndex
May 26, 20268-KMaterial eventDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 7, 20268-KMaterial eventDocumentIndex
May 7, 202610-QQuarterly reportDocumentIndex
Apr 9, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 27, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 4, 20268-KMaterial eventDocumentIndex
Mar 4, 202610-KAnnual reportDocumentIndex
Feb 17, 2026SC 13GPassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 17, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 4, 20268-KMaterial eventDocumentIndex
Jan 8, 20268-KMaterial eventDocumentIndex
Jan 5, 2026SC 13GPassive 5%+ stakeDocumentIndex
Dec 31, 20258-KMaterial eventDocumentIndex